Immunome (NASDAQ:IMNM) Announces Quarterly Earnings Results

Immunome (NASDAQ:IMNM) issued its quarterly earnings data on Wednesday. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.16), Zacks reports. Immunome had a negative return on equity of 48.63% and a negative net margin of 3,014.59%.

Immunome Stock Up 2.5 %

IMNM traded up $0.21 during trading on Wednesday, reaching $8.57. 522,477 shares of the stock traded hands, compared to its average volume of 810,302. The stock has a market capitalization of $683.69 million, a PE ratio of -1.06 and a beta of 1.93. The stock’s 50-day moving average is $9.89 and its 200 day moving average is $11.66. Immunome has a 12 month low of $8.34 and a 12 month high of $26.70.

Insider Buying and Selling at Immunome

In other Immunome news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the acquisition, the chief executive officer now directly owns 669,636 shares of the company’s stock, valued at approximately $5,189,679. The trade was a 28.87 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

IMNM has been the subject of a number of analyst reports. Lifesci Capital initiated coverage on shares of Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research report on Monday, March 10th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $27.17.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.